VS Media Announces Receipt of Nasdaq Minimum Bid Price Notification

HONG KONG, Dec. 29, 2023 (GLOBE NEWSWIRE) -- VS Media Holdings Limited (NASDAQ: VSME, the “Company”), a leader in managing a global network of digital creators, announced today that today announced that it received written notification on December 27, 2023, from The Nasdaq Stock Market LLC that it no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market pursuant to the Nasdaq Listing Rule 5550(a)(2).

The closing bid price for the Company's ordinary shares had fallen below $1.00 per share for 33 consecutive business days and accordingly, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market pursuant to the Nasdaq Listing Rule 5550(a)(2). However the Nasdaq Listing Rules also provide the Company a compliance period of 180 calendar days (i.e. by June 24, 2024) in which to regain compliance. If the Company chooses to implement a reverse stock split, it must complete the split no later than ten business days prior to June 24, 2024 (i.e. June 7, 2024).

If at any time during this 180 day period, the closing bid price of the Company's ordinary shares is at least $1.00 for a minimum of ten consecutive business days, the Company will be provided with written confirmation of compliance and the matter will be closed.

In the event the Company does not regain compliance, it may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, the Nasdaq will inform that Company that it has been granted an additional 180 calendar days. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, its ordinary shares will be subject to delisting.